000			01762 a2200457 4500
005			20250517013935.0
264		0	_c20150413
008			201504s 0 0 eng d
022			_a1538-7445
024	7		_a10.1158/0008-5472.CAN-14-2593 _2doi
040			_aNLM _beng _cNLM
100	1		_aCeccaldi, Raphael
245	0	0	_aA unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. _h[electronic resource]
260			_bCancer research _cFeb 2015
300			_a628-34 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
650	0	4	_aBRCA1 Protein _xgenetics
650	0	4	_aBRCA2 Protein _xgenetics
650	0	4	_aCarboplatin _xadministration & dosage
650	0	4	_aCarcinoma, Ovarian Epithelial
650	0	4	_aCisplatin _xadministration & dosage
650	0	4	_aDNA Breaks, Double-Stranded _xdrug effects
650	0	4	_aDNA Repair _xgenetics
650	0	4	_aDisease-Free Survival
650	0	4	_aDrug Resistance, Neoplasm _xgenetics
650	0	4	_aEnzyme Inhibitors _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aNeoplasms, Glandular and Epithelial _xdrug therapy
650	0	4	_aOvarian Neoplasms _xdrug therapy
650	0	4	_aPoly(ADP-ribose) Polymerase Inhibitors
650	0	4	_aPoly(ADP-ribose) Polymerases _xgenetics
700	1		_aO'Connor, Kevin W
700	1		_aMouw, Kent W
700	1		_aLi, Adam Y
700	1		_aMatulonis, Ursula A
700	1		_aD'Andrea, Alan D
700	1		_aKonstantinopoulos, Panagiotis A
773	0		_tCancer research _gvol. 75 _gno. 4 _gp. 628-34
856	4	0	_uhttps://doi.org/10.1158/0008-5472.CAN-14-2593 _zAvailable from publisher's website
999			_c24577744 _d24577744